Activity of novel oxazolidinones against Nocardia brasiliensis growing within THP-1 macrophages

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 5, 2009, Pages

  Vera Cabrera, Lucio ^a   Espinoza González, Nelly A ^a   Welsh, Oliverio ^a   Ocampo Candiani, Jorge ^a   Castro Garza, Jorge ^b  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Actinomycetoma; DA 7218; DA 7867; Linezolid

Indexed keywords

DA 7157; DA 7218; LINEZOLID; OXAZOLIDINONE DERIVATIVE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ORGANOPHOSPHATE; OXAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CELL LINE; CONTROLLED STUDY; FLUOROMETRY; HUMAN; HUMAN CELL; INHIBITION KINETICS; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MONOCYTE; NOCARDIA BRASILIENSIS; NONHUMAN; BACTERIAL COUNT; CYTOSOL; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; NOCARDIA;

ANTI-BACTERIAL AGENTS; CELL LINE; COLONY COUNT, MICROBIAL; CYTOSOL; HUMANS; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; NOCARDIA; OXAZOLES; PHOSPHORIC ACID ESTERS; TETRAZOLES;

EID: 73949089313     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp314     Document Type: Article

References (15)

1. Lopez Martinez R, Mendez Tovar LJ, Lavalle P et al. [Epidemiology of mycetoma in Mexico: study of 2105 cases]. Gac Med Mex 1992; 128: 477-81.
2. Welsh O, Vera-Cabrera L, Salinas-Carmona MC. Mycetoma. Clin Dermatol 2007; 25: 195-202.
3. Moylett EH, Pacheco SE, Brown-Elliott BA et al. Clinical experience with linezolid for the treatment of Nocardia infection. Clin Infect Dis 2003; 36: 313-8.
4. Park IN, Hong SB, Oh YM et al. Efficacy and tolerability of dailyhalf dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006; 58: 701-4.
5. Espinoza-González NA, Welsh O, de Torres NW et al. Efficacy of DA-7218, a new oxazolidinone prodrug, in the treatment of experimental actinomycetoma produced by Nocardia brasiliensis. Molecules 2008; 13: 31-40.
6. Vera-Cabrera L, Gonzalez E, Choi SH et al. In vitro activities of new antimicrobials against Nocardia brasiliensis. Antimicrob Agents Chemother 2004; 48: 602-4.
7. Vera-Cabrera L, Gonzalez E, Rendon A et al. In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis. Antimicrob Agents Chemother 2006; 50: 3170-2.
8. Vera-Cabrera L, Daw-Garza A, Said-Fernández S et al. Therapeutic effect of a novel oxazolidinone, DA-7867, in BALB/c mice infected with Nocardia brasiliensis. PLoS Negl Trop Dis 2008; 2: e289.
9. Salinas-Carmona MC, Zúñiga JM, Pérez-Rivera LI et al. Nocardia brasiliensis modulates IFN-gamma, IL-10, and IL-12 cytokine production by macrophages from BALB/c mice. J Interferon Cytokine Res 2009; 29: 263-71.
10. National Committee for Clinical Laboratory Standards. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes: Approved Standard M24-A. NCCLS, Wayne, PA, USA, 2003.
11. Beaman BL, Smathers M. Interaction of Nocardia asteroides with cultured rabbit alveolar macrophages. Infect Immun 1976; 13: 1126-31.
12. Beaman BL. In vitro response of rabbit alveolar macrophages to infection with Nocardia asteroides. Infect Immun 1977; 15: 925-37.
13. Shiloh MU, Ruan J, Nathan C. Evaluation of bacterial survival and phagocyte function with a fluorescence-based microplate assay. Infect Immun 1997; 65: 3193-8.
14. Prokocimer P, Bien P, Muñoz KA et al. Human pharmacokinetics of the prodrug TR-701 and TR-700, its active moiety, after multiple oral doses of 200 and 400 mg TR-701, a novel oxazolidinone. In: Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2008. Abstract F1-2064, p. 311. American Society for Microbiology, Washington, DC, USA.
15. Louie A, Fregeau C, Liu W et al. Pharmacodynamics of TR-701 in a mouse thigh infection model against Staphylococcus aureus ATCC 33591, a methicillin-resistant isolate. In: Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2008. Abstract A-985, p. 23. American Society for Microbiology, Washington, DC, USA.